
After Novo and Lilly resolved GLP-1 shortages, where does the compounding industry stand? Experts weigh in
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent implosion of Novo’s partnership with telehealth firm Hims & Hers suggests there is still very much a demand for imitation weight loss …